Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 14

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 14
---
2</div>

Between April and December 2023, the Company conducted another private placement of units of its securities at $3.20 price per unit (the “Second Private Placement Offering”), offering to accredited investors units of securities, where each unit (a “Unit” and collectively the “Units”) comprised of (i) two (2) shares of the Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock exercisable until December 31, 2026, at a per share exercise price of $2.40. In consideration of proceeds in the amount of $4,631.25 thousands received from the subscribers in the Second Private Placement Offering, we issued to these investors an aggregate of 2,894,532 of the Company’s Common Stock and warrants to purchase an additional 1,447,266 shares of Common Stock. The shares of Common Stock sold in the above offerings and shares of Common Stock underlying the Investor Warrants issued by the Company to these investors are included in this registration statement of which this Prospectus is a part thereof. Corporate Information Our principal executive offices are located at 10 HaMenofim Street, Herzliya, Israel, and our phone number is 1 800 519-1687. Our website iswww.reviumrx.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this Prospectus, and you should not consider information on our website to be part of this Prospectus. Implications of Being an Emerging Growth Company As a company with less than US$1.07 billion in revenue for our last fiscal year, the Company qualifies as an “emerging growth company” pursuant to the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable generally to public companies. These provisions include, but are not limited to:

| ● | being permitted to present                                                                                                     
 only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial 
 Condition and Results of Operations in our SEC filings;                                                                        |

| ● | not being required to comply                                                        
 with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; |

| ● | reduced disclosure obligations                                                                          
 regarding executive compensation in periodic reports, proxy statements and registration statements; and |

| ● | exemptions from the requirements